Aditxt, Inc. (NASDAQ:ADTX) Sees Significant Decline in Short Interest

Aditxt, Inc. (NASDAQ:ADTX) was the target of a large decline in short interest during the month of May. As of May 15th, there was short interest totaling 91,437 shares, a decline of 62.6% from the April 30th total of 244,575 shares. Approximately 277.1% of the shares of the company are sold short. Based on an average daily volume of 5,980,521 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Ratings Changes

Several analysts have weighed in on the company. Wall Street Zen upgraded Aditxt to a “sell” rating in a research note on Saturday, May 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Aditxt in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Aditxt Stock Down 7.0%

Shares of Aditxt stock traded down $0.01 during mid-day trading on Monday, reaching $0.11. 16,151,899 shares of the stock traded hands, compared to its average volume of 1,138,959. The business has a 50-day moving average of $10.77 and a 200 day moving average of $210.94. Aditxt has a fifty-two week low of $0.09 and a fifty-two week high of $53,451.08. The stock has a market capitalization of $89,380.00, a PE ratio of 0.00 and a beta of 0.84.

Aditxt (NASDAQ:ADTX) last announced its earnings results on Tuesday, March 31st. The company reported $315,563.31 EPS for the quarter. Aditxt had a negative return on equity of 374.60% and a negative net margin of 360,152.50%.

Aditxt Company Profile

Aditxt, Inc is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt’s approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.

The company’s product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols.